| -HOW WE GOT INTO THIS FINANCIAL AND ECONOMIC CRISIS AND WHAT IMPLICATIONS IT HAS FOR THE PRACTICE OF MEDICINE IN SINGAPORE R Act-on Singapore Med J 50 (6), 648, 2009 | | 2009 |
| " Fast food" may induce pre-diabetes impairing testicular function in rats JE Cavaco, L Rato, MG Alves, TR Dias, G Lopes, S Socorro, PF Oliveira HUMAN REPRODUCTION 28, 123-124, 2013 | | 2013 |
| (P09) Combined Use of Radiosurgery With Concurrent PD-1/PD-L1 Inhibition For Metastatic Brain Lesions of NSCLC G Azzam, W Park, E Mellon, A Markoe, N Elsayyad, G Lopes, ... International Journal of Radiation Oncology, Biology, Physics 101 (2), E24, 2018 | 5 | 2018 |
| 1. En pacientes con CPCNP metastásico,¿ cuáles son las pruebas diagnósticas moleculares y de inmunohisto-química que se deben realizar para definir tratamiento oncológico de … AV Ospina, R Brugés, M Lema, G de Lima Lopes Jr, M Provencio, ... HEMATOLOGÍA Y ONCOLOGÍA, 0 | | |
| 1027 Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations M Samora, P Aguiar, G Stock, B Gutierres, D Rodrigues, G Lopes, ... European Journal of Cancer 3 (51), S154, 2015 | | 2015 |
| 1066P Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC) A Trabolsi, E Rodriguez, S Kareff, JAO Gallegos, J Yin, P Walker, ... Annals of Oncology 33, S1041, 2022 | | 2022 |
| 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations MR Melia, E Auclin, MAM Lamas, N Dempsey, M Majem, R Lobefaro, ... Annals of Oncology 32, S940-S941, 2021 | 3 | 2021 |
| 1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC) M Vrohlings, S Jungmichel, I Tosevski, A Vantellini, P Knobel, N Sanchez, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 143 Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for NoneSmall-Cell Lung Cancer W Park, G Lopes, J Pacheco, PA Bunn, A Winther-Larsen, EBF Ebert, ... | | |
| 1601P Estimated years of potential life lost due to absence of pembrolizumab in SUS G Lenz, RA Pellegrini, LS Lago, PS Azevedo, LL Tôrres, G Lopes Annals of Oncology 31, S965, 2020 | | 2020 |
| 1602P Estimated years of potential life lost from lack of access to crizotinib: NSCLC ALK+ BD Cruz, G Lenz, RA Pellegrini, LS Lago, PS Azevedo, LL Tôrres, ... Annals of Oncology 31, S966, 2020 | | 2020 |
| 1605P Number of untimely deaths prevented with ALK-inhibitors in Brazilian patients with advanced non-small cell lung cancer with ALK driver mutations RA Pellegrini, G Lenz, BD Cruz, LS Lago, PS Azevedo, LL Tôrres, ... Annals of Oncology 31, S967, 2020 | | 2020 |
| 1723P CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC A Seeber, Y Baca, J Xiu, S Puri, TK Owonikoko, T Oliver, K Kerrigan, ... Annals of Oncology 33, S1325, 2022 | | 2022 |
| 1771P Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer JAO Gallegos, E Rodriguez, A Trabolsi, S Kareff, J Yin, P Walker, ... Annals of Oncology 33, S1347, 2022 | | 2022 |
| 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) M Hu, V Subbiah, LJ Wirth, M Schuler, AS Mansfield, MS Brose, ... Annals of Oncology 31, S1084, 2020 | 49 | 2020 |
| 195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042 T Mok, YL Wu, S Sadowski, J Zhang, R Rangwala, D Kush, ... Journal of Thoracic Oncology 11 (4), S142, 2016 | 7 | 2016 |
| 2826 Definitive chemoradiotherapy for loco-regionally advanced squamous cell head and neck cancer: Is cisplatin more effective than carboplatin?-a systematic review and meta … P Aguiar Jr, I Santoro, H Tadokoro, G Lopes, BA Filardi, PC Muniz, ... European Journal of Cancer 3 (51), S566-S567, 2015 | 1 | 2015 |
| 3080 Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker P Aguiar Jr, I Santoro, H Tadokoro, BA Filardi, GL Lopes, FS Picon, ... European Journal of Cancer 3 (51), S624, 2015 | | 2015 |
| 3122 The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis I Santoro, H Tadokoro, G Lopes, BA Filardi, CM Barreto, PC Muniz, ... EUROPEAN JOURNAL OF CANCER 51 (1), S644-S644, 2015 | 1 | 2015 |
| 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell … G de Castro, I Kudaba, YL Wu, G Lopes, DM Kowalski, HZ Turna, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 10 | 2021 |
Ben HaalandUniversity of Utah在 hsc.utah.edu 的电子邮件经过验证
